Detalhe da pesquisa
1.
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Cancer
; 130(3): 400-409, 2024 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864520
2.
Metastatic extraneural glioblastoma diagnosed with molecular testing.
Oncologist
; 2024 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38837109
3.
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Oncologist
; 29(4): e514-e525, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38297981
4.
Innovative trial design in precision oncology.
Semin Cancer Biol
; 84: 284-292, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33022355
5.
Transcriptomics and solid tumors: The next frontier in precision cancer medicine.
Semin Cancer Biol
; 84: 50-59, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32950605
6.
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Cancer
; 129(14): 2201-2213, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37016732
7.
Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors.
Br J Cancer
; 129(2): 266-274, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37173365
8.
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
Oncologist
; 28(12): 1100-e1292, 2023 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37311055
9.
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Gynecol Oncol
; 168: 76-82, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36423446
10.
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
Invest New Drugs
; 40(1): 124-133, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34559346
11.
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
Invest New Drugs
; 40(2): 290-299, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34562230
12.
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.
Cancer
; 127(3): 391-402, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33119140
13.
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
Br J Cancer
; 124(9): 1533-1539, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33674736
14.
Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors.
Oncologist
; 26(7): 558-e1098, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33491277
15.
Overview of Ocular Side Effects of Selinexor.
Oncologist
; 26(7): 619-623, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33728727
16.
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials.
Oncologist
; 26(7): 588-596, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33783054
17.
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Invest New Drugs
; 39(5): 1357-1365, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33909232
18.
Factors affecting symptom presentation in an early-phase clinical trials clinic patient population.
Invest New Drugs
; 38(4): 1166-1174, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31761957
19.
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours.
Br J Clin Pharmacol
; 86(9): 1836-1848, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32207164
20.
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
Cancer
; 125(3): 463-472, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30383888